Richard Surma is a seasoned estates professional with over 25 years of experience in leading R&D, scientific, and highly technical environments, particularly within the regulated development and built environment sectors. Currently serving as the Head of Estate Development & Capital Programmes at AstraZeneca, Richard plays...
Richard Surma is a seasoned estates professional with over 25 years of experience in leading R&D, scientific, and highly technical environments, particularly within the regulated development and built environment sectors. Currently serving as the Head of Estate Development & Capital Programmes at AstraZeneca, Richard plays a pivotal role in shaping the future of the UK R&D Estates Development function. His primary responsibility is the development and execution of a comprehensive Strategic Estates Masterplan, which is vital for aligning AstraZeneca’s physical infrastructure with its ambitious research and development objectives.
In this capacity, Richard oversees the creation of a capital masterplan that not only supports the Strategic Estates Masterplan but also ensures that all projects are meticulously scoped and aligned with senior leadership's vision. His expertise in project planning and management, bolstered by PRINCE2 certification, allows him to navigate complex capital approval processes, ensuring timely decision-making and efficient project delivery. Richard is adept at stakeholder management, fostering collaboration among diverse teams to drive sustainable development initiatives that resonate with AstraZeneca’s commitment to environmental stewardship.
Key projects under Richard’s leadership include the integration of sustainable practices into the estate development process, enhancing the operational efficiency of AstraZeneca’s facilities while minimizing environmental impact. His strategic approach to program management and team leadership ensures that all initiatives not only meet regulatory requirements but also advance the company’s long-term goals. With a keen focus on innovation and sustainability, Richard Surma continues to make significant contributions to AstraZeneca’s mission of delivering life-changing medicines.
